ストックスクリーナーアプリを入手
4.90
1.45%
0.07
プレマーケット:
4.74
-0.16
-3.27%
前日終値:
$4.83
開ける：
$5.07
24時間の取引高:
48,279
Relative Volume:
0.39
時価総額：
$10.89M
収益：
$895.50K
当期純損益:
$-26.30M
株価収益率:
-2.9878
EPS:
-1.64
ネットキャッシュフロー:
$-23.84M
1週間 パフォーマンス:
-7.37%
1か月 パフォーマンス:
-26.65%
6か月 パフォーマンス:
-64.90%
1年 パフォーマンス:
-88.66%
1日の値動き範囲:
$4.5601
$5.0901
1週間の範囲:
$4.45
$6.81
52週間の値動き範囲:
$3.65
$48.80
Mainz Biomed N V Stock (MYNZ) Company Profile
MYNZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
4.90 | 10.89M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | 開始されました | H.C. Wainwright | Buy |
Mainz Biomed N V (MYNZ) 最新ニュース
Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com
Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World
MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Mainz Biomed N.V. Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Marketscreener.com
Mainz Biomed Partners with Quest Diagnostics to Advance Colorectal Cancer Screening in the U.S. - Citybuzz
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq
Mainz Biomed (MYNZ) Stock Soars In Pre-Hour Session On A New Partnership - Stocks Telegraph
Mainz Biomed stock higher on Quest deal (MYNZ:NASDAQ) - Seeking Alpha
Mainz Biomed partners with Quest for colorectal cancer test - Investing.com
Mainz Biomed Forms Agreement with Quest Diagnostics to - GlobeNewswire
Mainz Biomed Partners with Quest Diagnostics for Major Colorectal Cancer Screening Study - StockTitan
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline - Investing.com
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline By Investing.com - Investing.com South Africa
Mainz Biomed Secures $8 Million in Follow-On Offering - TipRanks
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - GlobeNewswire
Mainz Biomed Secures $8M Through Strategic Follow-on Offering with Dual-Warrant Structure - StockTitan
Mainz Biomed prices $8M offering of shares and warrants - MSN
Mainz Biomed Prices $8 Million Follow-On Offering to Boost Diagnostics Operations - TipRanks
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules - The Manila Times
Mainz Biomed Announces $8M Follow-On Offering with Dual Warrant Structure - StockTitan
Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga
Mainz Biomed stock hits 52-week low at $0.18 amid market challenges - Investing.com India
Mainz Biomed announces 1-for-40 reverse stock split - Medical Buyer
Mainz Biomed (NASDAQ:MYNZ) Shares Set to Reverse Split on Tuesday, December 3rd - Defense World
Mainz Biomed Announces Stock Split - GlobeNewswire
Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues | MYNZ Stock News - StockTitan
Q3 EPS Estimates for Mainz Biomed Increased by HC Wainwright - Defense World
Mainz Biomed (NASDAQ:MYNZ) Rating Lowered to “Neutral” at HC Wainwright - Defense World
What You Didn’t Know About Mainz Biomed N.V (NASDAQ: MYNZ) This Week - Stocks Register
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test - Nasdaq
Mainz Biomed and Thermo Fisher Scientific sign a collaboration agreement - Wiley
Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance - TipRanks
MAINZ BIOMED NV- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - Citybuzz
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq
Mainz Biomed N.V. and Thermo Fisher Scientific Inc. Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Marketscreener.com
Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire
Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough | MYNZ Stock News - StockTitan
Mainz Biomed Partners with Thermo Fisher to Advance Colorectal Cancer Screening - Contract Pharma
Is Now The Time To Buy Mainz Biomed N.V. (NASDAQ: MYNZ) Stock? - Stocks Register
Mainz Biomed’s half-yearly revenue increases 4% YoY - Medical Buyer
Mainz Biomed restructured operations, implemented cost reductions - Yahoo Finance
Mainz Biomed reports revenue growth and reduced losses By Investing.com - Investing.com South Africa
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed Highlights Growth and Innovations for 2025 - TipRanks
Mainz Biomed N : MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Form 6 K - Marketscreener.com
Financial Metrics Unveiled: Mainz Biomed N.V. (MYNZ)’s Key Ratios in the Spotlight - The Dwinnex
Mainz Biomed N V (MYNZ) 財務データ
収益
当期純利益
現金流量
EPS
2.28%
大文字化:
|
ボリューム (24 時間):